NR3C1, ABCB1, TNF and CYP2C19 Polymorphisms Association with the Response to the Treatment of Erythema Nodosum Leprosum

Abstract

Aim: To evaluate the effects of gene polymorphisms in the treatment of erythema nodosum leprosum with prednisone/thalidomide. Patients & methods: A total of 152 patients from different regions of Brazil were included. Generalized estimating equation was used to evaluate the influence of polymorphisms and haplotypes on the drug dose variation throughout the treatment. Results: An association between the genotype tuberculoid of polymorphism ABCB1 3435C>T (rs1045642; p = 0.02) and prednisone dose was found in the recessive model. An association between the haplotypes 1031T/-863C/-857C/-308A/-238G (p = 0.006) and 1031T/-863C/-857T/-308A/-238G (p = 0.040) of the TNF gene and the CYP2C19*2 polymorphism were also identified, in relation to thalidomide dosage variation over the course of treatment. Conclusion: This work presents the first pharmacogenetic report of association between gene polymorphisms and erythema nodosum leprosum treatment with prednisone/thalidomide.

Keywords::

• erythema nodosum leprosum
• pharmacogenomics
• treatment

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.future-science.com/doi/suppl/10.2217/pgs-2018-0192

Acknowledgments

The authors would like to thank those who helped in obtaining the samples at all the participating centers of the study, to Movimento de Reintegração das Pessoas Atingidas pela Hanseníase (MORHAN) and the statistician Luciano Santos Pinto Guimarães for assistance with statistical analyses.

Financial & competing interest disclosure

Financial support was provided by INAGEMP (Instituto Nacional de Genética Médica Populacional; CNPq Process 573993/2008-4), FIPE/HCPA (GPPG no. 10-0410) and Coordenação Brasileira de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

The manuscript has been translated by a specialized company.

Ethical conduct of research

The authors state that they have obtained appropriate Institutional Review Board approval (10-0410). In addition, specimens were obtained from patients with informed consent.

Additional information

Funding

Financial support was provided by INAGEMP (Instituto Nacional de Genética Médica Populacional; CNPq Process 573993/2008-4), FIPE/HCPA (GPPG no. 10-0410) and Coordenação Brasileira de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The manuscript has been translated by a specialized company.